Press release
AL Amyloidosis Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma
"AL Amyloidosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market.
The AL Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the AL Amyloidosis Pipeline Report: https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel AL Amyloidosis treatment therapies with a considerable amount of success over the years.
• AL Amyloidosis companies working in the treatment market are HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others, are developing therapies for the AL Amyloidosis treatment
• Emerging AL Amyloidosis therapies in the different phases of clinical trials are- LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others are expected to have a significant impact on the AL Amyloidosis market in the coming years.
• In May 2025, Prothena Corporation plc (NASDAQ: PRTA) announced that its Phase 3 AFFIRM-AL clinical trial evaluating birtamimab for AL amyloidosis did not meet its primary endpoint (HR=0.915, p=0.7680). Consequently, the company has decided to discontinue the development of birtamimab and will also end the open-label extension phase of the AFFIRM-AL study.
• In February 2025, Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and immune-mediated conditions, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its sterically-optimized CAR-T therapy, NXC-201, for the treatment of relapsed/refractory AL amyloidosis. As of June 2024, fewer than half of RMAT requests submitted over the past eight years have received approval. The RMAT designation is reserved for advanced regenerative therapies targeting serious illnesses that show potential-through early clinical data-to treat, modify, reverse, or cure disease and address unmet medical needs.
• In January 2025, Attralus, Inc., a clinical-stage biopharmaceutical company developing novel therapies for systemic amyloidosis, in collaboration with Brigham and Women's Hospital in Boston, MA, has announced the enrollment of the first patient in the Phase 3 REVEAL study. This clinical trial is evaluating the investigational diagnostic imaging agent 124I-evuzamitide (AT-01) in individuals suspected of having cardiac amyloidosis. The study aims to determine the sensitivity and specificity of 124I-evuzamitide PET/CT imaging for diagnosing the condition. Dr. Sharmila Dorbala, Principal Investigator and Sponsor of the REVEAL study, emphasized the significance of the research, noting that the imaging technique offers a promising noninvasive approach to detecting amyloid deposits in the heart and other organs. Given the serious nature of cardiac amyloidosis, early and accurate diagnosis is critical. With the availability of FDA-approved treatments, a reliable diagnostic scan could play a crucial role in minimizing diagnostic delays and improving patient outcomes.
AL Amyloidosis Overview
AL amyloidosis (also known as light chain amyloidosis) is a rare and serious condition caused by the buildup of abnormal proteins called amyloid light chains in organs and tissues. These proteins are produced by malfunctioning plasma cells in the bone marrow and can accumulate in the heart, kidneys, liver, and nerves, leading to organ damage. Symptoms vary depending on the organs affected and may include fatigue, swelling, shortness of breath, and irregular heartbeat. Early diagnosis and treatment-often involving chemotherapy or stem cell transplant-are essential to prevent irreversible organ damage and improve outcomes.
Get a Free Sample PDF Report to know more about AL Amyloidosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging AL Amyloidosis Drugs Under Different Phases of Clinical Development Include:
• LambdaMab: HaemaLogiX
• ZN d5: Zentalis Pharmaceuticals
• STI-6129: Sorrento Therapeutics
• Isatuximab: Sanofi
• Bendamustine: Astellas Pharma GmbH
• Belantamab mafodotin: GlaxoSmithKline
• Ixazomib: Takeda Oncology
• CAEL-101: Caelum Biosciences
AL Amyloidosis Route of Administration
AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
AL Amyloidosis Molecule Type
AL Amyloidosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
AL Amyloidosis Pipeline Therapeutics Assessment
• AL Amyloidosis Assessment by Product Type
• AL Amyloidosis By Stage and Product Type
• AL Amyloidosis Assessment by Route of Administration
• AL Amyloidosis By Stage and Route of Administration
• AL Amyloidosis Assessment by Molecule Type
• AL Amyloidosis by Stage and Molecule Type
DelveInsight's AL Amyloidosis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further AL Amyloidosis product details are provided in the report. Download the AL Amyloidosis pipeline report to learn more about the emerging AL Amyloidosis therapies at:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the AL Amyloidosis Therapeutics Market include:
Key companies developing therapies for AL Amyloidosis are - Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and others.
AL Amyloidosis Pipeline Analysis:
The AL Amyloidosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.
• AL Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about AL Amyloidosis drugs and therapies:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
AL Amyloidosis Pipeline Market Drivers
• Increase in the number of patients suffering from AL Amyloidosis, increase in awareness about the disease are some of the important factors that are fueling the AL Amyloidosis Market.
AL Amyloidosis Pipeline Market Barriers
• However, high cost of the associated treatment, side effects associated with the treatment and other factors are creating obstacles in the AL Amyloidosis Market growth.
Scope of AL Amyloidosis Pipeline Drug Insight
• Coverage: Global
• Key AL Amyloidosis Companies: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others
• Key AL Amyloidosis Therapies: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others
• AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies
• AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
Request for Sample PDF Report for AL Amyloidosis Pipeline Assessment and clinical trials:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. AL Amyloidosis Report Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis Overview
4. AL Amyloidosis- Analytical Perspective In-depth Commercial Assessment
5. AL Amyloidosis Pipeline Therapeutics
6. AL Amyloidosis Late Stage Products (Phase II/III)
7. AL Amyloidosis Mid Stage Products (Phase II)
8. AL Amyloidosis Early Stage Products (Phase I)
9. AL Amyloidosis Preclinical Stage Products
10. AL Amyloidosis Therapeutics Assessment
11. AL Amyloidosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. AL Amyloidosis Key Companies
14. AL Amyloidosis Key Products
15. AL Amyloidosis Unmet Needs
16 . AL Amyloidosis Market Drivers and Barriers
17. AL Amyloidosis Future Perspectives and Conclusion
18. AL Amyloidosis Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma here
News-ID: 4103542 • Views: …
More Releases from DelveInsight Business Research
Global Hearing Aid Devices Market to grow at a CAGR of 5.45% by 2030, Evaluates …
According to DelveInsight's analysis, The growing prevalence of hearing loss is a key driver accelerating the hearing aid market. Moreover, increased exposure to loud sounds-stemming from environmental noise and workplace hazards-leads to more cases of noise-induced hearing loss, further fueling demand for hearing aid devices.
Additionally, heightened awareness, expanded screening programs for hearing loss, and a surge in product development activities are significant factors contributing to the market's growth during…
Global CDMO Market to grow at a CAGR of 7.25% by 2032, Evaluates DelveInsight
According to DelveInsight's analysis, The Contract Development and Manufacturing Organization (CDMO) market is witnessing rapid growth driven by the rising incidence of chronic diseases like cancer, cardiovascular conditions, and diabetes, which fuel demand for innovative treatments.
Additionally, the growing need for biologics and small molecules, valued for their effectiveness against complex illnesses, is broadening the scope of outsourced drug development and manufacturing. Strategic moves such as mergers, acquisitions, partnerships, and…
Chlamydia Infections Pipeline 2025: Detailed Clinical Trials and FDA-Approved Th …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chlamydia Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Chlamydia Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Chlamydia Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Postoperative Pain Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials E …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Postoperative Pain pipeline constitutes 40+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Postoperative Pain Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Postoperative Pain Market.
The Postoperative…
More Releases for Amyloidosis
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684
This latest report researches the industry structure,…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
Amyloidosis Treatment Market Size - Forecasts to 2026
As per the research conducted by GME, the Amyloidosis Treatment Market will grow with a CAGR value of 6.8 percent. The global amyloidosis treatment market is foreseen to rise rapidly throughout the forecast period because of the increasing likelihood of amyloidosis targeted therapies releases, a growing core patient demographic since they are biologically prone to amyloidosis, surging healthcare understanding amongst individuals, and increasing disposable incomes of consumers.
Browse 151 Market Data…
